

**To:** 5.1.2e [redacted]@inmi.it[ 5.1.2e [redacted]@inmi.it]  
**Cc:** 5.1.2e [redacted] 5.1.2e [redacted]@rivm.nl]  
**From:** 5.1.2e [redacted]  
**Sent:** Fri 4/3/2020 1:47:09 PM  
**Subject:** FW: herd immunity studies in Italy ? request for information from IMMI  
**Received:** Fri 4/3/2020 1:47:11 PM  
**C1** [NL73474.100.20 IIV-450 protocol V2.0 20200320.pdf](#)

Dear 5.1.2e [redacted]

I hope all is well with you.

I'm very happy to share our study design and protocols. Serosurveillance is an usefull tool in monitoring immunity/protection in large groups/population.

The serosurvey which 5.1.2e [redacted] mentioned is a longitudinal prospective study nested from a population based serosurvey in 2016/2017; Aim is to monitor seroprevalence of antibodies against SARS-Cov-2 in the Dutch population over time, asses antibody persistence (waning) and quality of antibody response.

In 2016/2017 the RIVM conducted a population based serosurvey, ages 0-89 years of age and national coverage. Aim was to investigate seroprevalence against (primary aim; vaccine preventable) infectious diseases. We have collected extensive data about these participants and stored biological material in biobank originating 2016/2017.

From this study we invited participants to join the current PIENTER Corona study. They are asked to donate a blood sample, multiple follow up times in the next months-1.5 year starting from now. The blood sample can be collected at home via a fingerprick in a microtube and sent back to our institute for antibody analysis. In addition there is a questionnaire to fill in which can be done by computer or on paper if requested.

Ofcourse dried blood spots are also possible and do not require any processing upon arrival at the lab besides storage at cooler/freezing temperatures.

I have attached the protocol for your convenience, but if you would like to receive the questionnaire, or other participant information material please do not hesitate to contact me,

And if you have further questions please let me know,

Regards,

5.1.2e [redacted]

5.1.2e [redacted]

5.1.2e [redacted] department Immunesurveillance  
 PI PIENTER and Health Study  
 PI PIENTER Corona

RIVM  
 Bilthoven  
 The Netherlands

---

**From:** 5.1.2e [redacted] <5.1.2e [redacted]@inmi.it>  
**Sent:** woensdag 1 april 2020 14:41  
**To:** 5.1.2e [redacted] <5.1.2e [redacted]@rivm.nl>; 5.1.2e [redacted] <5.1.2e [redacted]@sanquin.nl>  
**Cc:** 5.1.2e [redacted] <5.1.2e [redacted]@rivm.nl>; 5.1.2e [redacted] <5.1.2e [redacted]@inmi.it>  
**Subject:** R: herd immunity studies in Italy ? request for information from IMMI

Dear colleagues,

in Italy we are evaluating the possibility to start a study on SARS COV2 herd immunity in our population. To improve the study

design and compare strategy could you share details/protocols or the sero-prevalence studies ongoing in Netherlands and that you are coordinating.

Your help is really appreciated.

Best regards,

5.1.2e 5.1.2e

5.1.2e 2e 5.1.2e

5.1.2e Microbiology laboratory and infectious diseases biorepository

National Institute for Infectious Diseases 5.1.2e - IRCCS

Baglivi pavillion

Via Portuense 292

00149 Roma

Phone +39 5.1.2e

Mobile +39 5.1.2e

Email and Skype: 5.1.2e @inmi.it

PEC : 5.1.2e @pec.inmi.it

Da: 5.1.2e <5.1.2e @rivm.nl>

Inviato: mercoledì 1 aprile 2020 14:17

A: 5.1.2e <5.1.2e @inmi.it>

Cc: 5.1.2e <5.1.2e @rivm.nl>; 5.1.2e <5.1.2e @sanquin.nl>

Oggetto: herd immunity studies in Italy ? request for information from IMMI

Dear 5.1.2e

How are you doing? Good to hear from you in these bizarre times in Italy. Please take care. If I understood you correctly Italy is interested in our studies to assess herd immunity. Please find some brief info and contact persons here:

We have two sero-prevalence studies in the Netherlands one is coordinated by RIVM (1) and the other by Sanquin with support by RIVM (2)..

1. Is called the "PIENTER-study" contact person here is 5.1.2e 5.1.2e who is in cc. With specific time-intervals materials (dried-blot spots) will be collected for up to 5700 individuals (final number depends on the responses which we expect to be high) across the Netherlands in different age groups including meta data. Antibodies to SARS-CoV-2 will be measured and we hope to see build up of immunity in time. She can tell you all the details and has protocols.
2. Is based on blood donation screening: with specific time intervals (very four-six weeks) 7000 donations at each time point across the Netherlands will be screened for the presence of SARS-CoV-2 specific antibodies. Contact person here is 5.1.2e 5.1.2e who is in cc).

Best wishes 5.1.2e

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.  
[www.rivm.nl](http://www.rivm.nl) De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.

[www.rivm.nl/en](http://www.rivm.nl/en) Committed to health and sustainability